MCID: SMN008
MIFTS: 41

Semantic Dementia

Categories: Rare diseases, Mental diseases

Aliases & Classifications for Semantic Dementia

MalaCards integrated aliases for Semantic Dementia:

Name: Semantic Dementia 49 50 51 69
Semantic Primary Progressive Aphasia 49
Semantic Variant Ppa 49
Dementia - Semantic 50

Classifications:



External Ids:

UMLS 69 C0338462

Summaries for Semantic Dementia

NINDS : 50 Frontotemporal dementia (FTD) describes a clinical syndrome associated with shrinking of the frontal and temporal anterior lobes of the brain. Originally known as Pick’s disease, the name and classification of FTD has been a topic of discussion for over a century.  The current designation of the syndrome groups together Pick’s disease, primary progressive aphasia, and semantic dementia as FTD.  Some doctors propose adding corticobasal degeneration and progressive supranuclear palsy to FTD and calling the group Pick Complex.  These designations will continue to be debated.  As it is defined today, the symptoms of FTD fall into two clinical patterns that involve either (1) changes in behavior, or (2) problems with language.  The first type features behavior that can be either impulsive (disinhibited) or bored and listless (apathetic) and includes inappropriate social behavior; lack of social tact; lack of empathy; distractability; loss of insight into the behaviors of oneself and others; an increased interest in sex; changes in food preferences; agitation or, conversely, blunted emotions; neglect of personal hygiene; repetitive or compulsive behavior, and decreased energy and motivation.  The second type primarily features symptoms of language disturbance, including difficulty making or understanding speech, often in conjunction with the behavioral type’s symptoms.  Spatial skills and memory remain intact.  There is a strong genetic component to the disease; FTD often runs in families.

MalaCards based summary : Semantic Dementia, also known as semantic primary progressive aphasia, is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and frontotemporal dementia. An important gene associated with Semantic Dementia is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Neuroscience and Alzheimers Disease Pathway. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and temporal lobe, and related phenotypes are hematopoietic system and no phenotypic analysis

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Frontotemporal dementia.

Related Diseases for Semantic Dementia

Diseases related to Semantic Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 31.7 GRN MAPT RPS27A
2 frontotemporal dementia 30.8 APOE GRN MAPT PCBP2 RPS27A TARDBP
3 dementia 30.5 APOE GRN MAPT TARDBP
4 alexia 30.3 APOE TARDBP
5 aphasia 30.2 APOE GRN MAPT
6 pick disease of brain 30.1 APOE GRN MAPT RPS27A TARDBP
7 posterior cortical atrophy 30.0 APOE MAPT
8 progressive non-fluent aphasia 29.9 GRN MAPT
9 corticobasal degeneration 29.8 MAPT RPS27A TARDBP
10 alzheimer disease 29.7 APOE GRN MAPT TARDBP
11 apraxia 29.3 GRN MAPT
12 agraphia 29.1 GRN MAPT TARDBP
13 motor neuron disease 28.8 GRN MAPT RPS27A TARDBP
14 amyotrophic lateral sclerosis 1 28.5 GRN MAPT RPS27A TARDBP
15 supranuclear palsy, progressive, 1 28.3 APOE GRN MAPT RPS27A TARDBP
16 dyslexia 10.3
17 familial idiopathic basal ganglia calcification 10.2 APOE MAPT
18 hydrocephalus, normal-pressure 10.2 APOE MAPT
19 communicating hydrocephalus 10.2 APOE MAPT
20 binswanger's disease 10.2 APOE MAPT
21 postencephalitic parkinson disease 10.1 MAPT TARDBP
22 leukoencephalopathy, hereditary diffuse, with spheroids 10.1 MAPT RPS27A
23 alzheimer disease 2 10.1 APOE MAPT
24 neuronal intranuclear inclusion disease 10.1 MAPT RPS27A
25 cerebral amyloid angiopathy, cst3-related 10.1 APOE MAPT
26 neuronitis 10.1
27 spinocerebellar ataxia 11 10.1 MAPT TARDBP
28 brain injury 10.1 APOE MAPT
29 cerebritis 10.0
30 prosopagnosia 10.0
31 vascular dementia 10.0 APOE MAPT
32 blood group, i system 10.0
33 dysgraphia 10.0
34 aging 10.0
35 classic progressive supranuclear palsy syndrome 10.0
36 behavioral variant of frontotemporal dementia 9.9 GRN MAPT
37 echolalia 9.9 GRN MAPT
38 gait apraxia 9.9 APOE GRN
39 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 9.9 MAPT RPS27A
40 phonagnosia 9.9 GRN TARDBP
41 associative agnosia 9.9 GRN TARDBP
42 central nervous system disease 9.8 APOE MAPT TARDBP
43 synucleinopathy 9.8 MAPT RPS27A
44 lateral sclerosis 9.8
45 herpes simplex 9.8
46 encephalitis 9.8
47 polyarteritis nodosa, childhood-onset 9.8
48 hyperacusis 9.8
49 perry syndrome 9.8 GRN TARDBP
50 creutzfeldt-jakob disease 9.7 APOE MAPT

Graphical network of the top 20 diseases related to Semantic Dementia:



Diseases related to Semantic Dementia

Symptoms & Phenotypes for Semantic Dementia

MGI Mouse Phenotypes related to Semantic Dementia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.35 APOE GRN MAPT PCBP2 TARDBP
2 no phenotypic analysis MP:0003012 8.92 GRN MAPT TARDBP APOE

Drugs & Therapeutics for Semantic Dementia

Drugs for Semantic Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Citalopram Approved Phase 4 59729-33-8 2771
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
6 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
7
Serotonin Phase 4,Phase 3 50-67-9 5202
8 Serotonin Agents Phase 4,Phase 3
9 Serotonin Uptake Inhibitors Phase 4
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
11 Neurotransmitter Uptake Inhibitors Phase 4
12 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
14 Antidepressive Agents Phase 4,Phase 2,Phase 1
15 Antidepressive Agents, Second-Generation Phase 4
16 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
17 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
18 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
20 Antiparkinson Agents Phase 4,Phase 3,Phase 2
21 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Analgesics Phase 4,Phase 1
23 Analgesics, Non-Narcotic Phase 4,Phase 1
24 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
25 Anti-Inflammatory Agents Phase 4,Phase 1
26 cadexomer iodine Phase 4
27 Calamus Nutraceutical Phase 4
28
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
29
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
30
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
31
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
32
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
33
Methylene blue Approved, Investigational Phase 3 61-73-4
34
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
35
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
36
Iron Approved Phase 2, Phase 3 7439-89-6 23925
37
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
38 tannic acid Approved, Nutraceutical Phase 3
39
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
40 Prednisolone acetate Phase 2, Phase 3
41 Alkylating Agents Phase 2, Phase 3
42 Methylprednisolone acetate Phase 2, Phase 3
43 Methylprednisolone Hemisuccinate Phase 2, Phase 3
44 Glycoside Hydrolase Inhibitors Phase 3,Phase 2,Phase 1
45 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
46 Anti-HIV Agents Phase 3,Phase 2,Phase 1
47 Antilymphocyte Serum Phase 2, Phase 3
48 Prednisolone hemisuccinate Phase 2, Phase 3
49 Immunosuppressive Agents Phase 2, Phase 3
50 Prednisolone phosphate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 150)

# Name Status NCT ID Phase Drugs
1 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
2 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
3 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
4 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
5 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
6 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
7 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
8 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
9 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
10 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
11 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
12 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
13 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
14 SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfa Active, not recruiting NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)
15 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Enrolling by invitation NCT02245568 Phase 3 TRx0237
16 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
17 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
18 Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 Terminated NCT01473875 Phase 2, Phase 3 SBC-102
19 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
20 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
21 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
22 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
23 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
24 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
25 Electroencephalography (EEG) Biofeedback Training to Improve Executive Functioning and Memory in Adults With a Dementing Illness Completed NCT01168466 Phase 2
26 Double Blind Trial of DC Polarization in FTD Completed NCT00117858 Phase 2
27 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
28 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
29 Intranasal Oxytocin for Frontotemporal Dementia Recruiting NCT03260920 Phase 2 Syntocinon
30 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia Recruiting NCT02862210 Phase 2 Lithium Carbonate;Placebo
31 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Recruiting NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
32 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
33 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
34 F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis Recruiting NCT02414230 Phase 2 Drug: F 18 T807
35 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
36 Effects of Tolcapone on Frontotemporal Dementia Active, not recruiting NCT00604591 Phase 2 Tolcapone;Placebo
37 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Active, not recruiting NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
38 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
39 Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency Active, not recruiting NCT02193867 Phase 2 sebelipase alfa
40 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Enrolling by invitation NCT02676843 Phase 2 18F-AV-1451
41 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
42 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
43 F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) Withdrawn NCT02707978 Phase 2 F 18 T807
44 Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia Unknown status NCT00674960 Phase 1
45 Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment Unknown status NCT00149175 Phase 1
46 Far Infrared Radiation Treatment of Dementia and Other Mental Illness Unknown status NCT00574054 Phase 1
47 Safety Study of Intranasal Oxytocin in Frontotemporal Dementia Completed NCT01386333 Phase 1 oxytocin;Saline Nasal Mist
48 Direct Current Brain Polarization in Frontotemporal Dementia Completed NCT00077896 Phase 1
49 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
50 Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease Completed NCT00316498 Phase 1 OGT918

Search NIH Clinical Center for Semantic Dementia

Genetic Tests for Semantic Dementia

Anatomical Context for Semantic Dementia

MalaCards organs/tissues related to Semantic Dementia:

38
Brain, Testes, Temporal Lobe, Cortex, Prefrontal Cortex, Liver, Eye

Publications for Semantic Dementia

Articles related to Semantic Dementia:

(show top 50) (show all 352)
# Title Authors Year
1
Posterior Associative and Cingulate Cortex Involvement of Brain Single-Photon Emission Computed Tomography (SPECT) Imaging in Semantic Dementia with Probable Alzheimer Disease Pathology: A Case Report. ( 29429985 )
2018
2
Reading and visual word recognition ability in semantic dementia is not predicted by semantic performance. ( 29432768 )
2018
3
Semantic dementia and the left and right temporal lobes. ( 28947063 )
2017
4
A novel prion protein variant in a patient with semantic dementia. ( 28572272 )
2017
5
Semantic dementia, progressive non-fluent aphasia and their association with amyotrophic lateral sclerosis. ( 28554960 )
2017
6
Brain Network for the Core Deficits of Semantic Dementia: A Neural Network Connectivity-Behavior Mapping Study. ( 28579952 )
2017
7
Famous faces and voices: Differential profiles in early right and left semantic dementia and in Alzheimer's disease. ( 27916672 )
2017
8
Gustatory Dysfunction as an Early Symptom of Semantic Dementia. ( 29430242 )
2017
9
Rethinking the Cognitive Mechanisms Underlying Pantomime of Tool Use: Evidence from Alzheimer's Disease and Semantic Dementia. ( 28205493 )
2017
10
A SEMantic and EPisodic Memory Test (SEMEP) Developed within the Embodied Cognition Framework: Application to Normal Aging, Alzheimer's Disease and Semantic Dementia. ( 28955261 )
2017
11
Semantic word category processing in semantic dementia and posterior cortical atrophy. ( 28624681 )
2017
12
Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in Semantic Dementia but not with other TDP-43 pathological subtypes of Frontotemporal Lobar Degeneration. ( 28666471 )
2017
13
Cognitive consequences of the left-right asymmetry of atrophy in semantic dementia. ( 29289335 )
2017
14
Topological Alterations and Symptom-Relevant Modules in the Whole-Brain Structural Network in Semantic Dementia. ( 28731453 )
2017
15
What semantic dementia teaches us about the functional organization of the left posterior fusiform gyrus. ( 28951166 )
2017
16
Diverging Progression of Network Disruption and Atrophy in Alzheimer's Disease and Semantic Dementia. ( 27802229 )
2017
17
Semantic Dementia: A Mini-Review. ( 28019640 )
2016
18
Sensitivity of the Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II) to the Neurocognitive Deficits Associated with the Semantic Dementia Variant of Frontotemporal Lobar Degeneration: A Case Study. ( 27101084 )
2016
19
Distinct neural substrates of affective and cognitive theory of mind impairment in semantic dementia. ( 26998659 )
2016
20
Discovering EEG resting state alterations of semantic dementia. ( 27072087 )
2016
21
On the right side? A longitudinal study of left- versus right-lateralized semantic dementia. ( 26811253 )
2016
22
Preservation of episodic memory in semantic dementia: The importance of regions beyond the medial temporal lobes. ( 26683384 )
2016
23
Two cases of food aversion with semantic dementia. ( 26963051 )
2016
24
Successful short-term re-learning and generalisation of concepts in semantic dementia. ( 27677318 )
2016
25
Atrophy in Alzheimer's Disease andA Semantic Dementia: An ALE Meta-Analysis of Voxel-Based Morphometry Studies. ( 27567843 )
2016
26
Integrated PET/MRI imaging of semantic dementia. ( 27381147 )
2016
27
An update on semantic dementia: genetics, imaging, and pathology. ( 27915998 )
2016
28
Neuroeconomic dissociation of semantic dementia and behavioural variant frontotemporal dementia. ( 26667277 )
2016
29
Prosopagnosia as unusual presentation of semantic dementia: a case study. ( 27489094 )
2016
30
Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia. ( 27981671 )
2016
31
Amyloid deposition in semantic dementia: a positron emission tomography study. ( 26807731 )
2016
32
Somatic Symptom Disorder in Semantic Dementia: The Role of Alexisomia. ( 27647568 )
2016
33
Regularity and beyond: Impaired production and comprehension of inflectional morphology in semantic dementia. ( 26994740 )
2016
34
The Left Fusiform Gyrus is a Critical Region Contributing to the Core Behavioral Profile of Semantic Dementia. ( 27242479 )
2016
35
For richer or poorer? Imageability effects in semantic dementia patients' reading aloud. ( 25804665 )
2015
36
Vocabulary relearning in semantic dementia: Positive and negative consequences of increasing variability in the learning experience. ( 25585251 )
2015
37
Progressive Supranuclear Palsy Syndrome and Semantic Dementia in Neuropathologically Proven Lewy Body Disease: A Report of Two Cases. ( 26402758 )
2015
38
Relying on procedural memory to enhance independence in daily living activities: Smartphone use in a case of semantic dementia. ( 25558769 )
2015
39
Dissociated word production and comprehension in semantic dementia. ( 25987438 )
2015
40
Declining object recognition performance in semantic dementia: A case for stored visual object representations. ( 27355607 )
2015
41
"Knowing What You Don't Know": Language Insight in Semantic Dementia. ( 25720396 )
2015
42
Preservation of Person-Specific Semantic Knowledge in Semantic Dementia: Does Direct Personal Experience Have a Specific Role? ( 26635578 )
2015
43
Smartphone for smart living: Using new technologies to cope with everyday limitations in semantic dementia. ( 26483262 )
2015
44
Impairments in the Face-Processing Network in Developmental Prosopagnosia and Semantic Dementia. ( 26705265 )
2015
45
The Brain Connectivity Basis of Semantic Dementia: A Selective Review. ( 26336932 )
2015
46
Mechanical Problem-Solving Strategies in Alzheimer's Disease and Semantic Dementia. ( 26523522 )
2015
47
Characteristics of dyslexia and dysgraphia in a Chinese patient with semantic dementia. ( 24606031 )
2014
48
Living with semantic dementia: a case study of one family's experience. ( 24532121 )
2014
49
Progressive supranuclear palsy presenting initially as semantic dementia. ( 25516053 )
2014
50
Restoration of conceptual knowledge in a case of semantic dementia. ( 24592963 )
2014

Variations for Semantic Dementia

Expression for Semantic Dementia

Search GEO for disease gene expression data for Semantic Dementia.

Pathways for Semantic Dementia

Pathways related to Semantic Dementia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 APOE MAPT RPS27A TARDBP
2 10.61 APOE MAPT

GO Terms for Semantic Dementia

Biological processes related to Semantic Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of type I interferon production GO:0032480 8.96 PCBP2 RPS27A
2 virion assembly GO:0019068 8.62 APOE RPS27A

Molecular functions related to Semantic Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA binding GO:0003723 9.26 GRN PCBP2 RPS27A TARDBP
2 lipoprotein particle binding GO:0071813 8.62 APOE MAPT

Sources for Semantic Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....